We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Philips Healthcare

Operates in Diagnostic Imaging Systems, Patient Care and Clinical Informatics, Customer Services, and Home Healthcare... read more Featured Products: More products

Download Mobile App




Cardiac Troponin Assay Compared with Existing Tests

By LabMedica International staff writers
Posted on 02 May 2017
Print article
Image: The Minicare I-20 system, for rapid diagnosis of a heart attack at the point of care (Photo courtesy of Philips Healthcare).
Image: The Minicare I-20 system, for rapid diagnosis of a heart attack at the point of care (Photo courtesy of Philips Healthcare).
Efficient rule-out of acute myocardial infarction (MI) in patients presenting with symptoms of cardiac ischemia facilitates early disposition of the patient to outpatient care, and helps to relieve the increasing crowding of the emergency departments (ED) in most hospitals.

Sensitive cardiac troponin (cTn) assays support such a decision based on results at admission and three hours after admission, according to current guidelines. The time needed for results to become available from the hospital central laboratory often delays the disposition decision for another one or two hours.

An international team of scientists collaborating with those at the University of Uppsala compared a novel point-of-care assay (POC) for cardiac troponin I with a high-sensitivity cardiac troponin I laboratory assay. They enrolled 450 prospectively patients admitted with suspected MI at EDs or coronary care units/chest pain units of seven hospitals in Germany, France, Austria and the Netherlands. Patients eligible for enrolment were adults (age ≥ 18 years) who had presented with symptoms suggestive of MI. Only patients who presented for the first time and less than 12 hours from onset of symptom onset were included.

The novel cTnI POC test, the Minicare cTnI, provides a cTnI result within 10 minutes. The test was compared with two widely used cTnI assays: the Abbott Architect hs-cTnI and the POC Abbott I-Stat cTnI. The concentrations of cTnT in lithium-heparin plasma were measured at the local hospital laboratories using a hs-cTnT assay.

The team observed significant correlations for cTnI concentrations measured on the Minicare cTnI, either as whole blood or plasma, compared with the Architect hs-cTnI and I-Stat cTnI. There was evidence of bias for both comparisons: 0.59 (whole blood) and 0.48 (plasma) for the Architect hs-cTnI and 0.48 (whole blood) and 0.43 (plasma) for the I-Stat cTnI. The 8% discordant results among MI patients between Minicare cTnI and Architect hs-cTnI were almost equally distributed with 3% showing elevated concentrations with Minicare cTnI and 5% showing elevated results with Architect hs-cTnI, but non-elevated results with the other.

The authors concluded that that the novel Minicare cTnI POC assay equals the clinical performance in their patient cohort of a hs-cTnI assay. The Minicare cTnI assay, with a very high negative predictive value, may become suitable for prompt and safe rule-out of MI for patients with symptoms suggestive of MI in the emergency setting using a 0/3 hour sampling protocol. The study was published online on March 25, 2017, in the journal Clinica Chimica Acta.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.